Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01006 ...
Drug Name Letrozole
Molecular Weight 285.3027
Molecular Formula C17H11N5
CAS Number 112809-51-5
SMILES N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
External Links
DRUGBANK DB01006
T3DB T3D4803
PubChem Compound 3902
PDR 430
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 2.5 - 2.5 - Dave N, et al. 2015
Melting Point 184.5 ℃ 184-185 ℃ FDA Label

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
AUC 2.1 ng.h/ml 7387.0 nmol.h/L PO, oral; DRUGBANK
Bioavailability 99.0 % 99 % DRUGBANK
Bioavailability 99.9 % 99.9±16.3 % PO, oral; postmenopausal women; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 29.7 ng/ml 104 nmol/L PO, oral; DRUGBANK
C Max 32.8 ng/ml 115.0 nM postmenopausal women; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 8.1 h 8.1 h PO, oral; DRUGBANK
T Max 1.0 h 1.0 h postmenopausal women; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 1.5 L/h 1.52 L/h Total clearance; Single dose; DRUGBANK
Clearance 1.2 L/h 1.2 L/h Total clearance; at steady state; DRUGBANK
Clearance 0.0348 L/h/kg 0.58±0.21 ml/min/kg severe hepatic impairment ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.0342 L/h/kg 0.57 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 1.9 L/kg 1.87 L/kg DRUGBANK
Volume of Distribution 1.9 L/kg 1.87±0.46 L/kg The Pharmacological Basis of Therapeutics
Volume of Distribution 1.9 L/kg 1.9 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 42.0 h ~42 h elimination half-life; normal,healthy; breast cancer ↑ ; DRUGBANK
Half-life 45.0 h 45±16 h normal,healthy; postmenopausal women; The Pharmacological Basis of Therapeutics
Half-life 45.0 h 45 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 90.0 % 90 % Urinary excretion; DRUGBANK
Eliminate Route 6.0 % 6 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 3.9 % 3.9±1.4 % Urinary excretion; postmenopausal women; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 60.0 % 60 % DRUGBANK
Protein Binding 55.0 % 55 % DRUGBANK
Protein Binding 60.0 % 60 % postmenopausal women; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 2.5 mg/day 2.5 mg/day PO, oral Femara letrozole PDR
Max dose for adolescents 2.5 mg/day 2.5 mg/day PO, oral Femara letrozole PDR
Max dose for adults 2.5 mg/day 2.5 mg/day PO, oral Femara letrozole PDR
Max dose for adults 20.0 mg/dose 20 mg/dose PO, oral Femara letrozole PDR
Max dose for adults 7.5 mg/day 7.5 mg/day PO, oral Femara letrozole PDR
Max dose for geriatric 2.5 mg/day 2.5 mg/day PO, oral Femara letrozole PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1